[{"ID":"5b5b55160060a993494a74eaede81514","name":"Filing Review","objCode":"TASK","plannedCompletionDate":"Jul 24, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Enable Document Generation":"Yes","DE:Related Labeling Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b5b55160060a993494a74eaede81514\u0026activeTab\u003dcontent-dashboard__57741db80000c32805168d42405f4b6c","DE:Regulatory Search_2":"Filing Review","DE:Contains Document":"No","DE:Generic Drug Review Discipline":"Filing","DE:Related Chemistry Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b5b55160060a993494a74eaede81514\u0026activeTab\u003dcontent-dashboard__57741c820000c2b8a5b60a2f29cca894","DE:Related Microbiology Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b5b55160060a993494a74eaede81514\u0026activeTab\u003dcontent-dashboard__57741cc20000c2db420958ac1bcdf4bf","DE:Office View":"OGD","DE:Document Generator Link":"http://panoramaams-pps.preprod.fda.gov/services/exariWS/task?taskID\u003d5b5b55160060a993494a74eaede81514","DE:Custom IQA Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026activeTab\u003dcontent-dashboard__56d5e8c7003a1729408fb4dfee96a7c2"},"project":{"ID":"5b5b55110060a829fe1ecc1c0a6f5077","name":"ANDA-311758-ORIG-1","priority":0,"objCode":"PROJ","parameterValues":{"DE:Submission":"Original","DE:Submission Status Effective Date":"2018-07-27","DE:EDR Location":"\\\\CDSESUB1\\evsprod\\Testing\\ANDA-311758\\0000","DE:Application and Submission Type":"ANDA","DE:Cohort":"2018","DE:Submission Classification":"Unknown","DE:Mercado Application Number":"311758","DE:Submission Sub-Type":"Initial Submission","DE:Submission Format":"ECTD","DE:Regulatory Pathway":"505(j)","DE:GDRP Submission Type":"Original ANDA","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2019-01-10","DE:Submission Number":"1","DE:Market Availability":"Prescription","DE:GDUFA Goal Date":"2019-05-26","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d5b5b54e50060a072f6b7ccacc1fda66d","DE:Associated Drug Master File":"MF - 21430","DE:Referenced Application Number":"MF - 1627, MF - 21430, MF - 9025","DE:Target Action Date":"2019-05-26","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Quality Mid Review Date":"2019-01-10","DE:Supporting Document Number":"2","DE:Owner Due Date":"2019-05-12","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026atype\u003dANDA\u0026anum\u003d311758\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d2\u0026rcpdt\u003d7/27/18\u0026seq\u003d0000\u0026coreid\u003dci1513267611123.456187@fdsuv08640_tel\u0026appsts\u003dPending\u0026appstsdate\u003d7/27/18\u0026substs\u003dPending\u0026substsdate\u003d7/27/18","DE:GDUFA Congressional Performance":"Yes","DE:Responsible Organization":"CDER/OGD","DE:Core ID":"ci1513267611123.456187@fdsuv08640_tel","DE:Submit Date":"2018-07-27","DE:Quality Due Date":"2019-04-26","DE:PEPFAR":"Yes","DE:Labeling Mid Review Date":"2019-01-10","DE:Reason for Reopen":"N/A","DE:Reasons for Submission":"Original Application","DE:Application Number":"311758","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:Submission Status":"Pending","DE:Goal Date":"2019-05-26","DE:Submission Cycle":"Non-Original","DE:Acknowledgement Sent Date":"2018-07-31","DE:Prioritization Date":"2019-05-26","DE:Goals Determination":"Standard","DE:Mercado Application Type":"ANDA","DE:Assignable":"Yes","DE:Application Type":"ANDA","DE:Mid Cycle Date - TO BE DELETED":"1/24/19","DE:FDA Received Date":"2018-07-27","DE:eCTD Sequence Number":"0000"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[{"approvableObjCode":"TASK","approvableObjID":"5b5b55160060a993494a74eaede81514","approvalStepID":"5b5b55160060a996726c97beda609075","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b5b55160060a997936f0e8960b9f548","taskID":"5b5b55160060a993494a74eaede81514"},{"approvableObjCode":"TASK","approvableObjID":"5b5b55160060a993494a74eaede81514","approvalStepID":"5b5b55160060a9984b28a3bdce1eb381","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b5b55160060a9995a8151a64a531489","taskID":"5b5b55160060a993494a74eaede81514"},{"approvableObjCode":"TASK","approvableObjID":"5b5b55160060a993494a74eaede81514","approvalStepID":"5b5b55160060a996726c97beda609075","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b75abe800f45f804e58751c131acc6a","taskID":"5b5b55160060a993494a74eaede81514"},{"approvableObjCode":"TASK","approvableObjID":"5b5b55160060a993494a74eaede81514","approvalStepID":"5b5b55160060a9984b28a3bdce1eb381","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b75abe800f45f7fcc71a9b84b63e154","taskID":"5b5b55160060a993494a74eaede81514"}],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b6c6ad300c1524f28ffee33c63ddf7a","name":"Send Applicant Letter","objCode":"TASK","plannedCompletionDate":"Sep 2, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Enable Document Generation":"Yes","DE:Email Link":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b6c6ad300c1524f28ffee33c63ddf7a\u0026activeTab\u003dcontent-dashboard__540522110005cfc8e9148d951490ef86","DE:Custom Consult Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026activeTab\u003dcontent-dashboard__56c74da1013fa9acac6f89756a825fce","DE:Office View":"OM","DE:Document Generator Link":"http://panoramaams-pps.preprod.fda.gov/services/exariWS/task?taskID\u003d5b6c6ad300c1524f28ffee33c63ddf7a","DE:Custom IQA Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026activeTab\u003dcontent-dashboard__56d5e8c7003a1729408fb4dfee96a7c2"},"project":{"ID":"5b6c6ace00c151a20fc24e5ad44a1640","name":"ANDA-512117-SUPPL-1","priority":0,"objCode":"PROJ","parameterValues":{"DE:Submission":"Original","DE:Quality Due Date":"2019-05-09","DE:EDR Location":"\\\\CDSESUB1\\evsprod\\Testing\\ANDA-512117\\0000","DE:Submission Status Effective Date":"2018-08-17","DE:Cohort":"2018","DE:Application and Submission Type":"ANDA","DE:Submission Classification":"Unknown","DE:Labeling Mid Review Date":"2019-01-23","DE:Reason for Reopen":"N/A","DE:Mercado Application Number":"512117","DE:Application Number":"512117","DE:Submission Sub-Type":"Initial Submission","DE:Reasons for Submission":"ORIGINAL ANDA SUBMISSION","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:Submission Format":"ECTD","DE:Regulatory Pathway":"505(j)","DE:GDRP Submission Type":"Original ANDA","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2019-01-23","DE:Submission Number":"1","DE:Market Availability":"Prescription","DE:GDUFA Goal Date":"2019-06-08","DE:Goal Date":"2019-06-08","DE:Submission Status":"Tentative Approval","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d","DE:Submission Cycle":"Non-Original","DE:Prioritization Date":"2019-06-06","DE:Target Action Date":"2019-06-06","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Quality Mid Review Date":"2019-01-23","DE:Mercado Application Type":"ANDA","DE:Assignable":"Yes","DE:Owner Due Date":"2019-05-25","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026atype\u003dANDA\u0026anum\u003d512117\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d\u0026rcpdt\u003d8/9/18\u0026seq\u003d0000\u0026coreid\u003dci1513267611123.456187@fdsuv08640_tel\u0026appsts\u003d\u0026appstsdate\u003d\u0026substs\u003dTentative Approval\u0026substsdate\u003d8/17/18","DE:Application Type":"ANDA","DE:GDUFA Congressional Performance":"Yes","DE:Responsible Organization":"CDER/OGD","DE:Core ID":"ci1513267611123.456187@fdsuv08640_tel","DE:Submit Date":"2018-08-07","DE:Mid Cycle Date - TO BE DELETED":"2/6/19","DE:FDA Received Date":"2018-08-09","DE:eCTD Sequence Number":"0000"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b5b55160060ab91d024f2112dfcfc42","name":"Send Meeting Scheduled Letter","objCode":"TASK","plannedCompletionDate":"Aug 11, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Enable Document Generation":"Yes","DE:Email Link":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b5b55160060ab91d024f2112dfcfc42\u0026activeTab\u003dcontent-dashboard__540522110005cfc8e9148d951490ef86","DE:Custom Consult Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026activeTab\u003dcontent-dashboard__56c74da1013fa9acac6f89756a825fce","DE:Document Generator Link":"http://panoramaams-pps.preprod.fda.gov/services/exariWS/task?taskID\u003d5b5b55160060ab91d024f2112dfcfc42","DE:Custom IQA Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026activeTab\u003dcontent-dashboard__56d5e8c7003a1729408fb4dfee96a7c2"},"project":{"ID":"5b5b55110060a829fe1ecc1c0a6f5077","name":"ANDA-311758-ORIG-1","priority":0,"objCode":"PROJ","parameterValues":{"DE:Submission":"Original","DE:Submission Status Effective Date":"2018-07-27","DE:EDR Location":"\\\\CDSESUB1\\evsprod\\Testing\\ANDA-311758\\0000","DE:Application and Submission Type":"ANDA","DE:Cohort":"2018","DE:Submission Classification":"Unknown","DE:Mercado Application Number":"311758","DE:Submission Sub-Type":"Initial Submission","DE:Submission Format":"ECTD","DE:Regulatory Pathway":"505(j)","DE:GDRP Submission Type":"Original ANDA","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2019-01-10","DE:Submission Number":"1","DE:Market Availability":"Prescription","DE:GDUFA Goal Date":"2019-05-26","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d5b5b54e50060a072f6b7ccacc1fda66d","DE:Associated Drug Master File":"MF - 21430","DE:Referenced Application Number":"MF - 1627, MF - 21430, MF - 9025","DE:Target Action Date":"2019-05-26","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Quality Mid Review Date":"2019-01-10","DE:Supporting Document Number":"2","DE:Owner Due Date":"2019-05-12","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026atype\u003dANDA\u0026anum\u003d311758\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d2\u0026rcpdt\u003d7/27/18\u0026seq\u003d0000\u0026coreid\u003dci1513267611123.456187@fdsuv08640_tel\u0026appsts\u003dPending\u0026appstsdate\u003d7/27/18\u0026substs\u003dPending\u0026substsdate\u003d7/27/18","DE:GDUFA Congressional Performance":"Yes","DE:Responsible Organization":"CDER/OGD","DE:Core ID":"ci1513267611123.456187@fdsuv08640_tel","DE:Submit Date":"2018-07-27","DE:Quality Due Date":"2019-04-26","DE:PEPFAR":"Yes","DE:Labeling Mid Review Date":"2019-01-10","DE:Reason for Reopen":"N/A","DE:Reasons for Submission":"Original Application","DE:Application Number":"311758","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:Submission Status":"Pending","DE:Goal Date":"2019-05-26","DE:Submission Cycle":"Non-Original","DE:Acknowledgement Sent Date":"2018-07-31","DE:Prioritization Date":"2019-05-26","DE:Goals Determination":"Standard","DE:Mercado Application Type":"ANDA","DE:Assignable":"Yes","DE:Application Type":"ANDA","DE:Mid Cycle Date - TO BE DELETED":"1/24/19","DE:FDA Received Date":"2018-07-27","DE:eCTD Sequence Number":"0000"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[{"ID":"5b75a80900f442879e61068beb67c5f7","name":"ANDA-311758-ORIG-1_Send Acknowledgement","objCode":"DOCU","parameterValues":{},"approvals":[{"status":"NEW","approver":{"name":"David Gittes","objCode":"USER","accessLevel":{"rank":0}}}],"objectCategories":[],"versions":[],"currentVersion":{"objCode":"DOCV","docSize":0,"isProofable":false},"task":{"priority":0,"parameterValues":{},"documents":[],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]}}],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b6c6ad400c152f5a3c2ba09c92819ef","name":"Communicate filing decision and triage disciplines","objCode":"TASK","plannedCompletionDate":"Oct 8, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Template Email Task Type":"ANDA Filing Acknowledgement","DE:Email Link":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b6c6ad400c152f5a3c2ba09c92819ef\u0026activeTab\u003dcontent-dashboard__540522110005cfc8e9148d951490ef86","DE:Contains Document":"No","DE:Generic Drug Review Discipline":"Filing","DE:Access to Mandatory Data Entry Fields":"http://panoramaams-pps.preprod.fda.gov/PanoramaExtendedFramework/extendedform/docmgt/mandatorydataentry/index?projectID\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026taskID\u003d5b6c6ad400c152f5a3c2ba09c92819ef","DE:Office View":"OGD"},"project":{"ID":"5b6c6ace00c151a20fc24e5ad44a1640","name":"ANDA-512117-SUPPL-1","priority":0,"objCode":"PROJ","parameterValues":{"DE:Submission":"Original","DE:Quality Due Date":"2019-05-09","DE:EDR Location":"\\\\CDSESUB1\\evsprod\\Testing\\ANDA-512117\\0000","DE:Submission Status Effective Date":"2018-08-17","DE:Cohort":"2018","DE:Application and Submission Type":"ANDA","DE:Submission Classification":"Unknown","DE:Labeling Mid Review Date":"2019-01-23","DE:Reason for Reopen":"N/A","DE:Mercado Application Number":"512117","DE:Application Number":"512117","DE:Submission Sub-Type":"Initial Submission","DE:Reasons for Submission":"ORIGINAL ANDA SUBMISSION","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:Submission Format":"ECTD","DE:Regulatory Pathway":"505(j)","DE:GDRP Submission Type":"Original ANDA","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2019-01-23","DE:Submission Number":"1","DE:Market Availability":"Prescription","DE:GDUFA Goal Date":"2019-06-08","DE:Goal Date":"2019-06-08","DE:Submission Status":"Tentative Approval","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d","DE:Submission Cycle":"Non-Original","DE:Prioritization Date":"2019-06-06","DE:Target Action Date":"2019-06-06","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Quality Mid Review Date":"2019-01-23","DE:Mercado Application Type":"ANDA","DE:Assignable":"Yes","DE:Owner Due Date":"2019-05-25","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026atype\u003dANDA\u0026anum\u003d512117\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d\u0026rcpdt\u003d8/9/18\u0026seq\u003d0000\u0026coreid\u003dci1513267611123.456187@fdsuv08640_tel\u0026appsts\u003d\u0026appstsdate\u003d\u0026substs\u003dTentative Approval\u0026substsdate\u003d8/17/18","DE:Application Type":"ANDA","DE:GDUFA Congressional Performance":"Yes","DE:Responsible Organization":"CDER/OGD","DE:Core ID":"ci1513267611123.456187@fdsuv08640_tel","DE:Submit Date":"2018-08-07","DE:Mid Cycle Date - TO BE DELETED":"2/6/19","DE:FDA Received Date":"2018-08-09","DE:eCTD Sequence Number":"0000"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[{"approvableObjCode":"TASK","approvableObjID":"5b6c6ad400c152f5a3c2ba09c92819ef","approvalStepID":"5b6ca5be00c1ed8e65a295191c341e7d","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b6ca5be00c1ed905aea6c24bad177fb","taskID":"5b6c6ad400c152f5a3c2ba09c92819ef"},{"approvableObjCode":"TASK","approvableObjID":"5b6c6ad400c152f5a3c2ba09c92819ef","approvalStepID":"5b6ca5be00c1ed919a4279ca4c0348f6","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b6ca5be00c1ed93903936bbc2fb0935","taskID":"5b6c6ad400c152f5a3c2ba09c92819ef"},{"approvableObjCode":"TASK","approvableObjID":"5b6c6ad400c152f5a3c2ba09c92819ef","approvalStepID":"5b6ca5be00c1ed8e65a295191c341e7d","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b6ca5be00c1ed8f6bd99b98c2e155c3","taskID":"5b6c6ad400c152f5a3c2ba09c92819ef"},{"approvableObjCode":"TASK","approvableObjID":"5b6c6ad400c152f5a3c2ba09c92819ef","approvalStepID":"5b6ca5be00c1ed919a4279ca4c0348f6","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b6ca5be00c1ed9296eb3ecfb8eb9131","taskID":"5b6c6ad400c152f5a3c2ba09c92819ef"}],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b7ed4210014a21ed41e529fedf42203","name":"Labeling Review","objCode":"TASK","plannedCompletionDate":"Oct 2, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Related Labeling Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b7ed4210014a21ed41e529fedf42203\u0026activeTab\u003dcontent-dashboard__57741db80000c32805168d42405f4b6c","DE:Regulatory Search_2":"Labeling Review","DE:Contains Document":"No","DE:Generic Drug Review Discipline":"Labeling","DE:Related Chemistry Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b7ed4210014a21ed41e529fedf42203\u0026activeTab\u003dcontent-dashboard__57741c820000c2b8a5b60a2f29cca894","DE:Related Microbiology Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b7ed4210014a21ed41e529fedf42203\u0026activeTab\u003dcontent-dashboard__57741cc20000c2db420958ac1bcdf4bf","DE:Office View":"OGD","DE:Document Generator Link":"http://panoramaams-pps.preprod.fda.gov/services/exariWS/task?taskID\u003d5b7ed4210014a21ed41e529fedf42203","DE:Custom IQA Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b7ed4200014a087761302483ab5a6e8\u0026activeTab\u003dcontent-dashboard__56d5e8c7003a1729408fb4dfee96a7c2"},"project":{"ID":"5b7ed4200014a087761302483ab5a6e8","name":"Copy of ANDA-204006-ORIG-1-AMEND-10 [8/23 SMT]","priority":0,"objCode":"PROJ","parameterValues":{"DE:Application and Submission Type":"ANDA","DE:Cohort":"2012","DE:Active Ingredient":"ABACAVIR SULFATE || LAMIVUDINE || ZIDOVUDINE","DE:Responsible Official Country":"US","DE:Mercado Application Number":"204006","DE:Proprietary Name":"ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE","DE:Dosage Form":"Dosage Form  TABLET","DE:GDRP Submission Type":"Solicited Major Amendment","DE:Applicant/Sponsor/Holder Name":"MYLAN INSTITUTIONAL LLC","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2018-12-22","DE:Submission Number":"1","DE:GDUFA Goal Date":"2019-04-14","DE:State/Province":"IL","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d5a96ebd5002db8f51a53c772c11cd43b","DE:Therapeutic Class Number":"7030241","DE:Associated Drug Master File":"MF - 17751, MF - 18229, MF - 23431","DE:Address 1":"4901 HIAWATHA DR","DE:Referenced Application Number":"MF - 1016, MF - 10562, MF - 11711, MF - 16219, MF - 17751, MF - 18229, MF - 23431, MF - 2880, MF - 3782, MF - 4837, MF - 721, MF - 9869, NDA - 21205","DE:Target Action Date":"2019-04-14","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b7ed4200014a087761302483ab5a6e8\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Labeling Team Recommendation":"Team 2","DE:Quality Mid Review Date":"2018-12-22","DE:Responsible Official Address 1":"101 Main Street","DE:Supporting Document Number":"10","DE:Country":"US","DE:Owner Due Date":"2019-03-31","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b7ed4200014a087761302483ab5a6e8\u0026atype\u003dANDA\u0026anum\u003d204006\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d10\u0026rcpdt\u003d7/30/18\u0026seq\u003d\u0026coreid\u003d\u0026appsts\u003dApproved\u0026appstsdate\u003d11/23/16\u0026substs\u003dPending\u0026substsdate\u003d","DE:Responsible Official City":"Silver Spring","DE:GDUFA Congressional Performance":"Yes","DE:Submission Properties":"GDUFA Backlog - Yes \nGDUFA Backlog First Action Complete - Yes","DE:Quality Due Date":"2019-03-15","DE:Dosage Form Code":"DOSAGE FORM  TABLET","DE:Party ID":"120046495","DE:Responsible Official State/Province":"MD","DE:Labeling Mid Review Date":"2018-12-22","DE:Reason for Reopen":"N/A","DE:Application Number":"204006","DE:Supporting Document Sub-Category":"Amendment Verification Statement - Facility Information - After Action- Complete","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:City":"ROCKFORD","DE:Postal Code":"61103","DE:Responsible Official Title":"Consumer Safety","DE:Application RPM":"KREGER, JESSICA, E","DE:Responsible Official Postal Code":"20993","DE:Responsible Official First Name":"John","DE:Established Name":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Submission Status":"Pending","DE:Goal Date":"2019-04-14","DE:Submission Cycle":"Non-Original","DE:Acknowledgement Sent Date":"2018-08-23","DE:Prioritization Date":"2019-04-14","DE:Product":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Goals Determination":"Standard","DE:Mercado Application Type":"ANDA","DE:Postal Code Extension":"1287","DE:Supporting Document Category":"Amendment Correspondence - Quality - Resubmission","DE:PET":"Yes","DE:Application Type":"ANDA","DE:Responsible Official Last Name":"Smith","DE:Mid Cycle Date - TO BE DELETED":"1/5/19","DE:Route":"ORAL","DE:FDA Received Date":"2018-07-30"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[{"approvableObjCode":"TASK","approvableObjID":"5b7ed4210014a21ed41e529fedf42203","approvalStepID":"5b7ed4210014a223666d25cb61ddf488","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b7ed4210014a224cdc4aee716c59226","taskID":"5b7ed4210014a21ed41e529fedf42203"},{"approvableObjCode":"TASK","approvableObjID":"5b7ed4210014a21ed41e529fedf42203","approvalStepID":"5b7ed4210014a221c9f460e03bd9d961","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b7ed4210014a222b1ef63dc7a7ca794","taskID":"5b7ed4210014a21ed41e529fedf42203"}],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b7ed4210014a18690353b8c110aed30","name":"Clinical PK/PD Sites","objCode":"TASK","plannedCompletionDate":"Sep 1, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Contains Document":"No","DE:Generic Drug Review Discipline":"BE Inspections","DE:Office View":"OSE"},"project":{"ID":"5b7ed4200014a087761302483ab5a6e8","name":"Copy of ANDA-204006-ORIG-1-AMEND-10 [8/23 SMT]","priority":0,"objCode":"PROJ","parameterValues":{"DE:Application and Submission Type":"ANDA","DE:Cohort":"2012","DE:Active Ingredient":"ABACAVIR SULFATE || LAMIVUDINE || ZIDOVUDINE","DE:Responsible Official Country":"US","DE:Mercado Application Number":"204006","DE:Proprietary Name":"ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE","DE:Dosage Form":"Dosage Form  TABLET","DE:GDRP Submission Type":"Solicited Major Amendment","DE:Applicant/Sponsor/Holder Name":"MYLAN INSTITUTIONAL LLC","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2018-12-22","DE:Submission Number":"1","DE:GDUFA Goal Date":"2019-04-14","DE:State/Province":"IL","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d5a96ebd5002db8f51a53c772c11cd43b","DE:Therapeutic Class Number":"7030241","DE:Associated Drug Master File":"MF - 17751, MF - 18229, MF - 23431","DE:Address 1":"4901 HIAWATHA DR","DE:Referenced Application Number":"MF - 1016, MF - 10562, MF - 11711, MF - 16219, MF - 17751, MF - 18229, MF - 23431, MF - 2880, MF - 3782, MF - 4837, MF - 721, MF - 9869, NDA - 21205","DE:Target Action Date":"2019-04-14","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b7ed4200014a087761302483ab5a6e8\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Labeling Team Recommendation":"Team 2","DE:Quality Mid Review Date":"2018-12-22","DE:Responsible Official Address 1":"101 Main Street","DE:Supporting Document Number":"10","DE:Country":"US","DE:Owner Due Date":"2019-03-31","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b7ed4200014a087761302483ab5a6e8\u0026atype\u003dANDA\u0026anum\u003d204006\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d10\u0026rcpdt\u003d7/30/18\u0026seq\u003d\u0026coreid\u003d\u0026appsts\u003dApproved\u0026appstsdate\u003d11/23/16\u0026substs\u003dPending\u0026substsdate\u003d","DE:Responsible Official City":"Silver Spring","DE:GDUFA Congressional Performance":"Yes","DE:Submission Properties":"GDUFA Backlog - Yes \nGDUFA Backlog First Action Complete - Yes","DE:Quality Due Date":"2019-03-15","DE:Dosage Form Code":"DOSAGE FORM  TABLET","DE:Party ID":"120046495","DE:Responsible Official State/Province":"MD","DE:Labeling Mid Review Date":"2018-12-22","DE:Reason for Reopen":"N/A","DE:Application Number":"204006","DE:Supporting Document Sub-Category":"Amendment Verification Statement - Facility Information - After Action- Complete","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:City":"ROCKFORD","DE:Postal Code":"61103","DE:Responsible Official Title":"Consumer Safety","DE:Application RPM":"KREGER, JESSICA, E","DE:Responsible Official Postal Code":"20993","DE:Responsible Official First Name":"John","DE:Established Name":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Submission Status":"Pending","DE:Goal Date":"2019-04-14","DE:Submission Cycle":"Non-Original","DE:Acknowledgement Sent Date":"2018-08-23","DE:Prioritization Date":"2019-04-14","DE:Product":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Goals Determination":"Standard","DE:Mercado Application Type":"ANDA","DE:Postal Code Extension":"1287","DE:Supporting Document Category":"Amendment Correspondence - Quality - Resubmission","DE:PET":"Yes","DE:Application Type":"ANDA","DE:Responsible Official Last Name":"Smith","DE:Mid Cycle Date - TO BE DELETED":"1/5/19","DE:Route":"ORAL","DE:FDA Received Date":"2018-07-30"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b6472a80026951ca91542752a8aff28","name":"Labeling Review","objCode":"TASK","plannedCompletionDate":"Oct 2, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Related Labeling Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b6472a80026951ca91542752a8aff28\u0026activeTab\u003dcontent-dashboard__57741db80000c32805168d42405f4b6c","DE:Regulatory Search_2":"Labeling Review","DE:Contains Document":"No","DE:Generic Drug Review Discipline":"Labeling","DE:Related Chemistry Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b6472a80026951ca91542752a8aff28\u0026activeTab\u003dcontent-dashboard__57741c820000c2b8a5b60a2f29cca894","DE:Related Microbiology Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b6472a80026951ca91542752a8aff28\u0026activeTab\u003dcontent-dashboard__57741cc20000c2db420958ac1bcdf4bf","DE:Office View":"OGD","DE:Document Generator Link":"http://panoramaams-pps.preprod.fda.gov/services/exariWS/task?taskID\u003d5b6472a80026951ca91542752a8aff28","DE:Custom IQA Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b646faf00267fa9613e12a752c16dce\u0026activeTab\u003dcontent-dashboard__56d5e8c7003a1729408fb4dfee96a7c2"},"project":{"ID":"5b646faf00267fa9613e12a752c16dce","name":"ANDA-204006-ORIG-1-AMEND-10","priority":0,"objCode":"PROJ","parameterValues":{"DE:Application and Submission Type":"ANDA","DE:Cohort":"2012","DE:Active Ingredient":"ABACAVIR SULFATE || LAMIVUDINE || ZIDOVUDINE","DE:Responsible Official Country":"US","DE:Mercado Application Number":"204006","DE:Proprietary Name":"ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE","DE:Dosage Form":"Dosage Form  TABLET","DE:GDRP Submission Type":"Solicited Major Amendment","DE:Applicant/Sponsor/Holder Name":"MYLAN INSTITUTIONAL LLC","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2018-11-14","DE:Submission Number":"1","DE:GDUFA Goal Date":"2019-01-29","DE:State/Province":"IL","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d5a96ebd5002db8f51a53c772c11cd43b","DE:Therapeutic Class Number":"7030241","DE:Associated Drug Master File":"MF - 17751, MF - 18229, MF - 23431","DE:Address 1":"4901 HIAWATHA DR","DE:Referenced Application Number":"MF - 1016, MF - 10562, MF - 11711, MF - 16219, MF - 17751, MF - 18229, MF - 23431, MF - 2880, MF - 3782, MF - 4837, MF - 721, MF - 9869, NDA - 21205","DE:Target Action Date":"2019-04-14","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b646faf00267fa9613e12a752c16dce\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Labeling Team Recommendation":"Team 2","DE:Quality Mid Review Date":"2018-11-14","DE:Responsible Official Address 1":"101 Main Street","DE:Supporting Document Number":"10","DE:Country":"US","DE:Owner Due Date":"2019-01-15","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b646faf00267fa9613e12a752c16dce\u0026atype\u003dANDA\u0026anum\u003d204006\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d10\u0026rcpdt\u003d7/30/18\u0026seq\u003d\u0026coreid\u003d\u0026appsts\u003dApproved\u0026appstsdate\u003d11/23/16\u0026substs\u003dPending\u0026substsdate\u003d","DE:Responsible Official City":"Silver Spring","DE:GDUFA Congressional Performance":"Yes","DE:Submission Properties":"GDUFA Backlog - Yes \nGDUFA Backlog First Action Complete - Yes","DE:Quality Due Date":"2018-12-30","DE:Dosage Form Code":"DOSAGE FORM  TABLET","DE:Party ID":"120046495","DE:Responsible Official State/Province":"MD","DE:Labeling Mid Review Date":"2018-11-14","DE:Reason for Reopen":"N/A","DE:Application Number":"204006","DE:Supporting Document Sub-Category":"Amendment Verification Statement - Facility Information - After Action- Complete","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:City":"ROCKFORD","DE:Postal Code":"61103","DE:Responsible Official Title":"Consumer Safety","DE:Application RPM":"KREGER, JESSICA, E","DE:Responsible Official Postal Code":"20993","DE:Responsible Official First Name":"John","DE:Established Name":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Submission Status":"Pending","DE:Goal Date":"2019-01-29","DE:Submission Cycle":"Non-Original","DE:Acknowledgement Sent Date":"2018-08-20","DE:Prioritization Date":"2019-04-14","DE:Product":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Goals Determination":"Standard","DE:Mercado Application Type":"ANDA","DE:Postal Code Extension":"1287","DE:Supporting Document Category":"Amendment Correspondence - Quality - Resubmission","DE:PET":"Yes","DE:Application Type":"ANDA","DE:Responsible Official Last Name":"Smith","DE:Mid Cycle Date - TO BE DELETED":"11/28/18","DE:Route":"ORAL","DE:FDA Received Date":"2018-07-30"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[{"approvableObjCode":"TASK","approvableObjID":"5b6472a80026951ca91542752a8aff28","approvalStepID":"5b6472a80026951fdd5816d1d3e79866","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b6472a8002695200320ffb15ba73dae","taskID":"5b6472a80026951ca91542752a8aff28"},{"approvableObjCode":"TASK","approvableObjID":"5b6472a80026951ca91542752a8aff28","approvalStepID":"5b6472a800269521e185ba3d69e491df","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b6472a8002695220de0f072c7662bd6","taskID":"5b6472a80026951ca91542752a8aff28"}],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b7ed142001481c332867d30d102e99d","name":"Labeling Review","objCode":"TASK","plannedCompletionDate":"Oct 2, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Related Labeling Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b7ed142001481c332867d30d102e99d\u0026activeTab\u003dcontent-dashboard__57741db80000c32805168d42405f4b6c","DE:Regulatory Search_2":"Labeling Review","DE:Contains Document":"No","DE:Generic Drug Review Discipline":"Labeling","DE:Related Chemistry Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b7ed142001481c332867d30d102e99d\u0026activeTab\u003dcontent-dashboard__57741c820000c2b8a5b60a2f29cca894","DE:Related Microbiology Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b7ed142001481c332867d30d102e99d\u0026activeTab\u003dcontent-dashboard__57741cc20000c2db420958ac1bcdf4bf","DE:Office View":"OGD","DE:Document Generator Link":"http://panoramaams-pps.preprod.fda.gov/services/exariWS/task?taskID\u003d5b7ed142001481c332867d30d102e99d","DE:Custom IQA Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b7ed13e00148002f32b5295979de27d\u0026activeTab\u003dcontent-dashboard__56d5e8c7003a1729408fb4dfee96a7c2"},"project":{"ID":"5b7ed13e00148002f32b5295979de27d","name":"ANDA-204006-ORIG-1-AMEND-10 [8/23 SMT]","priority":0,"objCode":"PROJ","parameterValues":{"DE:Application and Submission Type":"ANDA","DE:Cohort":"2012","DE:Active Ingredient":"ABACAVIR SULFATE || LAMIVUDINE || ZIDOVUDINE","DE:Responsible Official Country":"US","DE:Mercado Application Number":"204006","DE:Proprietary Name":"ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE","DE:Dosage Form":"Dosage Form  TABLET","DE:GDRP Submission Type":"Solicited Major Amendment","DE:Applicant/Sponsor/Holder Name":"MYLAN INSTITUTIONAL LLC","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2018-12-22","DE:Submission Number":"1","DE:GDUFA Goal Date":"2019-04-14","DE:State/Province":"IL","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d5a96ebd5002db8f51a53c772c11cd43b","DE:Therapeutic Class Number":"7030241","DE:Associated Drug Master File":"MF - 17751, MF - 18229, MF - 23431","DE:Address 1":"4901 HIAWATHA DR","DE:Referenced Application Number":"MF - 1016, MF - 10562, MF - 11711, MF - 16219, MF - 17751, MF - 18229, MF - 23431, MF - 2880, MF - 3782, MF - 4837, MF - 721, MF - 9869, NDA - 21205","DE:Target Action Date":"2019-04-14","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b7ed13e00148002f32b5295979de27d\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Labeling Team Recommendation":"Team 2","DE:Quality Mid Review Date":"2018-12-22","DE:Responsible Official Address 1":"101 Main Street","DE:Supporting Document Number":"10","DE:Country":"US","DE:Owner Due Date":"2019-03-31","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b7ed13e00148002f32b5295979de27d\u0026atype\u003dANDA\u0026anum\u003d204006\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d10\u0026rcpdt\u003d7/30/18\u0026seq\u003d\u0026coreid\u003d\u0026appsts\u003dApproved\u0026appstsdate\u003d11/23/16\u0026substs\u003dPending\u0026substsdate\u003d","DE:Responsible Official City":"Silver Spring","DE:GDUFA Congressional Performance":"Yes","DE:Submission Properties":"GDUFA Backlog - Yes \nGDUFA Backlog First Action Complete - Yes","DE:Quality Due Date":"2019-03-15","DE:Dosage Form Code":"DOSAGE FORM  TABLET","DE:Party ID":"120046495","DE:Responsible Official State/Province":"MD","DE:Labeling Mid Review Date":"2018-12-22","DE:Reason for Reopen":"N/A","DE:Application Number":"204006","DE:Supporting Document Sub-Category":"Amendment Verification Statement - Facility Information - After Action- Complete","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:City":"ROCKFORD","DE:Postal Code":"61103","DE:Responsible Official Title":"Consumer Safety","DE:Application RPM":"KREGER, JESSICA, E","DE:Responsible Official Postal Code":"20993","DE:Responsible Official First Name":"John","DE:Established Name":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Submission Status":"Pending","DE:Goal Date":"2019-04-14","DE:Submission Cycle":"Non-Original","DE:Acknowledgement Sent Date":"2018-08-23","DE:Prioritization Date":"2019-04-14","DE:Product":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Goals Determination":"Standard","DE:Mercado Application Type":"ANDA","DE:Postal Code Extension":"1287","DE:Supporting Document Category":"Amendment Correspondence - Quality - Resubmission","DE:PET":"Yes","DE:Application Type":"ANDA","DE:Responsible Official Last Name":"Smith","DE:Mid Cycle Date - TO BE DELETED":"1/5/19","DE:Route":"ORAL","DE:FDA Received Date":"2018-07-30"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[{"approvableObjCode":"TASK","approvableObjID":"5b7ed142001481c332867d30d102e99d","approvalStepID":"5b7ed142001481c889f2c486ed348531","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b7ed142001481c9ace6b399cd1f0fca","taskID":"5b7ed142001481c332867d30d102e99d"},{"approvableObjCode":"TASK","approvableObjID":"5b7ed142001481c332867d30d102e99d","approvalStepID":"5b7ed142001481c6df46f187966b89ee","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b7ed142001481c75a0560a839662110","taskID":"5b7ed142001481c332867d30d102e99d"}],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b5b55160060a9de92e90c947684a40d","name":"Send Acknowledgement","objCode":"TASK","plannedCompletionDate":"Aug 12, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Enable Document Generation":"Yes","DE:Template Email Task Type":"ANDA Acknowledgement Communication","DE:Email Link":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b5b55160060a9de92e90c947684a40d\u0026activeTab\u003dcontent-dashboard__540522110005cfc8e9148d951490ef86","DE:Contains Document":"No","DE:Custom Consult Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026activeTab\u003dcontent-dashboard__56c74da1013fa9acac6f89756a825fce","DE:Generic Drug Review Discipline":"Other","DE:Office View":"OGD","DE:Document Generator Link":"http://panoramaams-pps.preprod.fda.gov/services/exariWS/task?taskID\u003d5b5b55160060a9de92e90c947684a40d","DE:Custom IQA Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026activeTab\u003dcontent-dashboard__56d5e8c7003a1729408fb4dfee96a7c2"},"project":{"ID":"5b5b55110060a829fe1ecc1c0a6f5077","name":"ANDA-311758-ORIG-1","priority":0,"objCode":"PROJ","parameterValues":{"DE:Submission":"Original","DE:Submission Status Effective Date":"2018-07-27","DE:EDR Location":"\\\\CDSESUB1\\evsprod\\Testing\\ANDA-311758\\0000","DE:Application and Submission Type":"ANDA","DE:Cohort":"2018","DE:Submission Classification":"Unknown","DE:Mercado Application Number":"311758","DE:Submission Sub-Type":"Initial Submission","DE:Submission Format":"ECTD","DE:Regulatory Pathway":"505(j)","DE:GDRP Submission Type":"Original ANDA","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2019-01-10","DE:Submission Number":"1","DE:Market Availability":"Prescription","DE:GDUFA Goal Date":"2019-05-26","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d5b5b54e50060a072f6b7ccacc1fda66d","DE:Associated Drug Master File":"MF - 21430","DE:Referenced Application Number":"MF - 1627, MF - 21430, MF - 9025","DE:Target Action Date":"2019-05-26","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Quality Mid Review Date":"2019-01-10","DE:Supporting Document Number":"2","DE:Owner Due Date":"2019-05-12","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b5b55110060a829fe1ecc1c0a6f5077\u0026atype\u003dANDA\u0026anum\u003d311758\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d2\u0026rcpdt\u003d7/27/18\u0026seq\u003d0000\u0026coreid\u003dci1513267611123.456187@fdsuv08640_tel\u0026appsts\u003dPending\u0026appstsdate\u003d7/27/18\u0026substs\u003dPending\u0026substsdate\u003d7/27/18","DE:GDUFA Congressional Performance":"Yes","DE:Responsible Organization":"CDER/OGD","DE:Core ID":"ci1513267611123.456187@fdsuv08640_tel","DE:Submit Date":"2018-07-27","DE:Quality Due Date":"2019-04-26","DE:PEPFAR":"Yes","DE:Labeling Mid Review Date":"2019-01-10","DE:Reason for Reopen":"N/A","DE:Reasons for Submission":"Original Application","DE:Application Number":"311758","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:Submission Status":"Pending","DE:Goal Date":"2019-05-26","DE:Submission Cycle":"Non-Original","DE:Acknowledgement Sent Date":"2018-07-31","DE:Prioritization Date":"2019-05-26","DE:Goals Determination":"Standard","DE:Mercado Application Type":"ANDA","DE:Assignable":"Yes","DE:Application Type":"ANDA","DE:Mid Cycle Date - TO BE DELETED":"1/24/19","DE:FDA Received Date":"2018-07-27","DE:eCTD Sequence Number":"0000"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[{"ID":"5b60c3ab00813630d418dfbcaf6677b7","name":"ANDA-311758-ORIG-1_Send Acknowledgement","objCode":"DOCU","parameterValues":{"DE:GDUFA Goal Date":"2019-05-26","DE:Template Automation ID":"5390d294-684c-490d-94b7-83a3be609a37","DE:Document Archival Status":"Archived","DE:Smart Template":"Acknowledgement Amendment.xml","DE:Access to Document Linking":"http://panoramaams-pps.preprod.fda.gov/PanoramaExtendedFramework/extendedform/docmgt/documentlink/index?documentID\u003d5b60c3ab00813630d418dfbcaf6677b7","DE:Amend Date":"2018-07-12","DE:Select the appropriate letter template":"ANDA Amendment Acknowledgement","DE:Document Signatory Authority":"Document Signatory Authority","DE:Goals Determination":"Standard"},"approvals":[{"status":"APPROVED","approver":{"name":"David Gittes","objCode":"USER","accessLevel":{"rank":0}}}],"objectCategories":[],"versions":[],"currentVersion":{"objCode":"DOCV","docSize":0,"isProofable":false},"task":{"priority":0,"parameterValues":{},"documents":[],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]}},{"ID":"5b64d2e2009a32a52d6b62abf85b05b8","name":"A311758N000DPM-AcknowledgementLetter01","objCode":"DOCU","parameterValues":{"DE:GDUFA Goal Date":"1990-01-01","DE:Smart Template":"Acknowledgement Amendment.xml","DE:Acknowledgement Sent Date":"2018-07-31","DE:Amendment Type":"Minor","DE:Access to Document Linking":"http://panoramaams-pps.preprod.fda.gov/PanoramaExtendedFramework/extendedform/docmgt/documentlink/index?documentID\u003d5b64d2e2009a32a52d6b62abf85b05b8","DE:Amend Date":"2018-07-12","DE:Linked Project/Program GUIDs":"5b5b81130061b806bad3b67ebfae472d","DE:Select the appropriate letter template":"ANDA Amendment Acknowledgement","DE:Document Signatory Authority":"Document Signatory Authority","DE:Goals Determination":"Priority with PFC","DE:Template Automation ID":"9773954d-c5a3-43d7-9a16-9d0101d5a434","DE:PFC Validation":"PFC Valid","DE:Linked Projects/Programs":"ANDA-311758-ORIG-2"},"approvals":[],"objectCategories":[],"versions":[],"currentVersion":{"objCode":"DOCV","docSize":0,"isProofable":false},"task":{"priority":0,"parameterValues":{},"documents":[],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]}},{"ID":"5b6114ac008219882126f64874b0b133","name":"ANDA-311758-ORIG-1_Send Acknowledgement","objCode":"DOCU","parameterValues":{"DE:GDUFA Goal Date":"2019-05-26","DE:Template Automation ID":"919ce221-1980-4872-9d90-c6b6db3a66df","DE:Document Archival Status":"Archived","DE:Smart Template":"Acknowledgement Amendment.xml","DE:Access to Document Linking":"http://panoramaams-pps.preprod.fda.gov/PanoramaExtendedFramework/extendedform/docmgt/documentlink/index?documentID\u003d5b6114ac008219882126f64874b0b133","DE:Amend Date":"2018-07-12","DE:Select the appropriate letter template":"ANDA Amendment Acknowledgement","DE:Document Signatory Authority":"Document Signatory Authority","DE:Goals Determination":"Standard"},"approvals":[{"status":"APPROVED","approver":{"name":"David Gittes","objCode":"USER","accessLevel":{"rank":0}}}],"objectCategories":[],"versions":[],"currentVersion":{"objCode":"DOCV","docSize":0,"isProofable":false},"task":{"priority":0,"parameterValues":{},"documents":[],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]}}],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b6c6ad400c152d5d61e2f2518547968","name":"Filing Review","objCode":"TASK","plannedCompletionDate":"Oct 5, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Enable Document Generation":"Yes","DE:Related Labeling Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b6c6ad400c152d5d61e2f2518547968\u0026activeTab\u003dcontent-dashboard__57741db80000c32805168d42405f4b6c","DE:Regulatory Search_2":"Filing Review","DE:Contains Document":"No","DE:Generic Drug Review Discipline":"Filing","DE:Related Chemistry Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b6c6ad400c152d5d61e2f2518547968\u0026activeTab\u003dcontent-dashboard__57741c820000c2b8a5b60a2f29cca894","DE:Related Microbiology Reviews":"http://panoramaams-pps.preprod.fda.gov/task/view?ID\u003d5b6c6ad400c152d5d61e2f2518547968\u0026activeTab\u003dcontent-dashboard__57741cc20000c2db420958ac1bcdf4bf","DE:Office View":"OGD","DE:Document Generator Link":"http://panoramaams-pps.preprod.fda.gov/services/exariWS/task?taskID\u003d5b6c6ad400c152d5d61e2f2518547968","DE:Custom IQA Link 2":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026activeTab\u003dcontent-dashboard__56d5e8c7003a1729408fb4dfee96a7c2"},"project":{"ID":"5b6c6ace00c151a20fc24e5ad44a1640","name":"ANDA-512117-SUPPL-1","priority":0,"objCode":"PROJ","parameterValues":{"DE:Submission":"Original","DE:Quality Due Date":"2019-05-09","DE:EDR Location":"\\\\CDSESUB1\\evsprod\\Testing\\ANDA-512117\\0000","DE:Submission Status Effective Date":"2018-08-17","DE:Cohort":"2018","DE:Application and Submission Type":"ANDA","DE:Submission Classification":"Unknown","DE:Labeling Mid Review Date":"2019-01-23","DE:Reason for Reopen":"N/A","DE:Mercado Application Number":"512117","DE:Application Number":"512117","DE:Submission Sub-Type":"Initial Submission","DE:Reasons for Submission":"ORIGINAL ANDA SUBMISSION","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:Submission Format":"ECTD","DE:Regulatory Pathway":"505(j)","DE:GDRP Submission Type":"Original ANDA","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2019-01-23","DE:Submission Number":"1","DE:Market Availability":"Prescription","DE:GDUFA Goal Date":"2019-06-08","DE:Goal Date":"2019-06-08","DE:Submission Status":"Tentative Approval","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d","DE:Submission Cycle":"Non-Original","DE:Prioritization Date":"2019-06-06","DE:Target Action Date":"2019-06-06","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Quality Mid Review Date":"2019-01-23","DE:Mercado Application Type":"ANDA","DE:Assignable":"Yes","DE:Owner Due Date":"2019-05-25","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b6c6ace00c151a20fc24e5ad44a1640\u0026atype\u003dANDA\u0026anum\u003d512117\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d\u0026rcpdt\u003d8/9/18\u0026seq\u003d0000\u0026coreid\u003dci1513267611123.456187@fdsuv08640_tel\u0026appsts\u003d\u0026appstsdate\u003d\u0026substs\u003dTentative Approval\u0026substsdate\u003d8/17/18","DE:Application Type":"ANDA","DE:GDUFA Congressional Performance":"Yes","DE:Responsible Organization":"CDER/OGD","DE:Core ID":"ci1513267611123.456187@fdsuv08640_tel","DE:Submit Date":"2018-08-07","DE:Mid Cycle Date - TO BE DELETED":"2/6/19","DE:FDA Received Date":"2018-08-09","DE:eCTD Sequence Number":"0000"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[{"approvableObjCode":"TASK","approvableObjID":"5b6c6ad400c152d5d61e2f2518547968","approvalStepID":"5b6c6ad400c152d84f0888cd4e77fe02","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b6c6ad400c152d944bda1c5ce1e0a90","taskID":"5b6c6ad400c152d5d61e2f2518547968"},{"approvableObjCode":"TASK","approvableObjID":"5b6c6ad400c152d5d61e2f2518547968","approvalStepID":"5b6c6ad400c152dacf69cfdb184e9995","customerID":"4f8718c70000050cc1ae8cec3171dcb8","isOverridden":false,"status":"NA","stepApproverID":"5b6c6ad400c152db2945ef2ee15547a7","taskID":"5b6c6ad400c152d5d61e2f2518547968"}],"auditTypes":[],"assignments":[],"objectCategories":[]},{"ID":"5b7ed140001480f8bd9728586cf23393","name":"Clinical PK/PD Sites","objCode":"TASK","plannedCompletionDate":"Sep 1, 2018 5:00:00 PM","priority":0,"status":"NEW","parameterValues":{"DE:Contains Document":"No","DE:Generic Drug Review Discipline":"BE Inspections","DE:Office View":"OSE"},"project":{"ID":"5b7ed13e00148002f32b5295979de27d","name":"ANDA-204006-ORIG-1-AMEND-10 [8/23 SMT]","priority":0,"objCode":"PROJ","parameterValues":{"DE:Application and Submission Type":"ANDA","DE:Cohort":"2012","DE:Active Ingredient":"ABACAVIR SULFATE || LAMIVUDINE || ZIDOVUDINE","DE:Responsible Official Country":"US","DE:Mercado Application Number":"204006","DE:Proprietary Name":"ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE","DE:Dosage Form":"Dosage Form  TABLET","DE:GDRP Submission Type":"Solicited Major Amendment","DE:Applicant/Sponsor/Holder Name":"MYLAN INSTITUTIONAL LLC","DE:Integrity Services Priority- TO BE DELETED":"0","DE:Bioequivalence Mid Review Date":"2018-12-22","DE:Submission Number":"1","DE:GDUFA Goal Date":"2019-04-14","DE:State/Province":"IL","DE:Form Link":"http://panoramaams-pps.preprod.fda.gov/program/view?ID\u003d5a96ebd5002db8f51a53c772c11cd43b","DE:Therapeutic Class Number":"7030241","DE:Associated Drug Master File":"MF - 17751, MF - 18229, MF - 23431","DE:Address 1":"4901 HIAWATHA DR","DE:Referenced Application Number":"MF - 1016, MF - 10562, MF - 11711, MF - 16219, MF - 17751, MF - 18229, MF - 23431, MF - 2880, MF - 3782, MF - 4837, MF - 721, MF - 9869, NDA - 21205","DE:Target Action Date":"2019-04-14","DE:Facility History Link":"http://panoramaams-pps.preprod.fda.gov/project/view?ID\u003d5b7ed13e00148002f32b5295979de27d\u0026activeTab\u003dcontent-dashboard__5661c53c00002c03a14b35608f31f23c","DE:Submission Type":"Original","DE:Labeling Team Recommendation":"Team 2","DE:Quality Mid Review Date":"2018-12-22","DE:Responsible Official Address 1":"101 Main Street","DE:Supporting Document Number":"10","DE:Country":"US","DE:Owner Due Date":"2019-03-31","DE:Contains Facility":"Yes","DE:Integrity Services UI":"projid\u003d5b7ed13e00148002f32b5295979de27d\u0026atype\u003dANDA\u0026anum\u003d204006\u0026stype\u003dOriginal\u0026snum\u003d1\u0026sdoc\u003d10\u0026rcpdt\u003d7/30/18\u0026seq\u003d\u0026coreid\u003d\u0026appsts\u003dApproved\u0026appstsdate\u003d11/23/16\u0026substs\u003dPending\u0026substsdate\u003d","DE:Responsible Official City":"Silver Spring","DE:GDUFA Congressional Performance":"Yes","DE:Submission Properties":"GDUFA Backlog - Yes \nGDUFA Backlog First Action Complete - Yes","DE:Quality Due Date":"2019-03-15","DE:Dosage Form Code":"DOSAGE FORM  TABLET","DE:Party ID":"120046495","DE:Responsible Official State/Province":"MD","DE:Labeling Mid Review Date":"2018-12-22","DE:Reason for Reopen":"N/A","DE:Application Number":"204006","DE:Supporting Document Sub-Category":"Amendment Verification Statement - Facility Information - After Action- Complete","DE:Group Report Link":"http://panoramaams-pps.preprod.fda.gov/advancedSearch?objCode\u003dPROJ\u0026allowRedirect\u003dfalse\u0026query\u003d\u0026queryMapJSON\u003d{%22DE:Group%20Submission%20ID%22:%22%22,%22DE:Group%20Submission%20ID_Mod%22:%22cieq%22}\u0026valueLabelsJSON\u003d{%22Group%20Submission%20ID%22:[]}","DE:City":"ROCKFORD","DE:Postal Code":"61103","DE:Responsible Official Title":"Consumer Safety","DE:Application RPM":"KREGER, JESSICA, E","DE:Responsible Official Postal Code":"20993","DE:Responsible Official First Name":"John","DE:Established Name":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Submission Status":"Pending","DE:Goal Date":"2019-04-14","DE:Submission Cycle":"Non-Original","DE:Acknowledgement Sent Date":"2018-08-23","DE:Prioritization Date":"2019-04-14","DE:Product":"ABACAVIR SULFATE;LAMIVUDINE; ZIDOVUDINE","DE:Goals Determination":"Standard","DE:Mercado Application Type":"ANDA","DE:Postal Code Extension":"1287","DE:Supporting Document Category":"Amendment Correspondence - Quality - Resubmission","DE:PET":"Yes","DE:Application Type":"ANDA","DE:Responsible Official Last Name":"Smith","DE:Mid Cycle Date - TO BE DELETED":"1/5/19","DE:Route":"ORAL","DE:FDA Received Date":"2018-07-30"},"tasks":[],"documents":[],"objectCategories":[],"portfolio":{"aligned":0.0,"budget":0.0,"netValue":0.0,"onBudget":0.0,"onTime":0.0,"roi":0.0,"objectCategories":[]}},"documents":[],"approverStatuses":[],"auditTypes":[],"assignments":[],"objectCategories":[]}]
